At the end of 2005, six European countries had implemented public immunization campaigns with serogroup C conjugate vaccines, and all had experienced substantial declines in the incidence of serogroup C disease. A quadrivalent ACWY meningococcal vaccine is in use in the USA, but serogroup A is extremely rare in Europe and serogroups Y and W135 are infrequent causes of disease. This paper outlines recommendations on the use of conjugate vaccines in Europe based on the experience with meningococcal C conjugate (MCC) vaccines so far. © 2006 Federation of European Microbiological Societies.
CITATION STYLE
Trotter, C. L., & Ramsay, M. E. (2007, January). Vaccination against meningococcal disease in Europe: Review and recommendations for the use of conjugate vaccines. FEMS Microbiology Reviews. https://doi.org/10.1111/j.1574-6976.2006.00053.x
Mendeley helps you to discover research relevant for your work.